OBJECTIVE： To evaluate the clinical efficacy of Shuanghuanglian injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）， and to observe its effects on the plasma levels of C-reactive protein （CRP）， procalcitonin （PCT） and interleukin-6 （IL-6）. METHODS： A total of 100 AECOPD patients were randomly divided into observation group and control group， with 50 cases in each group. Control group received routine treatment， such as controlled oxygen therapy， intravenous dripping of moxifloxacin， bronchodilator for relieving asthma， mucolytic for eliminating phlegm， nutritional support. Observation group was additionally given Shuanghuanglian injection 1 ml/（kg·d）added into 5％ Glucose injection 250 ml intravenously， qd， on the basis of control group. Treatment course of 2 groups lasted for 10 d. Clinical efficacies of 2 groups were compared as well as the changes of serum levels of CRP， PCT and IL-6 before and after treatment and the occurrence of ADR. RESULTS： After treatment， total effective rate of observation group was 96.0％， which was significantly higher than 82.0％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in serum levels of CRP， PCT and IL-6 between 2 groups （P＞0.05）. After treatment， serum levels of CRP， PCT and IL-6 were decreased significantly in 2 groups， and those of observation group were significantly lower than those of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Shuanghuanglian injection can effectively improve serum inflammatory factors of AECOPD patients， and shows good clinical efficacy and safety.